

Funnel plot of comparison: 1 IIEF-EF change scores: blinding across 4 RoB domains, outcome: 1.2 Effect estimate intervention groups.

Figure 4 (Analysis 6.1)

Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI
SIL001	2.3	0.67989	2.0%	2.30 [0.97, 3.63]
SIL002	5.2	0.663129	2.0%	5.20 [3.90, 6.50]
SIL003	3.6	0.714299	1.9%	3.60 [2.20, 5.00]
SIL006	6.38	0.966705	1.5%	6.38 [4.49, 8.27]
SIL007	0.3	1.753625	0.8%	0.30 [-3.14, 3.74]
SIL011	3.4	1.000253	1.5%	3.40 [1.44, 5.36]
SIL014	1.86	0.961774	1.5%	1.86 [-0.03, 3.75]
SIL016	2.2	0.899509	1.6%	2.20 [0.44, 3.96]
SIL017	1.4	0.599619	2.1%	1.40 [0.22, 2.58]
SIL018	0.2	0.599656	2.1%	0.20 [-0.98, 1.38]
SIL022	2.1	0.418374	2.4%	2.10 [1.28, 2.92]
SIL023	2.2	0.381528	2.5%	2.20 [1.45, 2.95]
SIL024	2.6	1.080105	1.4%	2.60 [0.48, 4.72]
SIL025	1.4	1.000253	1.5%	1.40 [-0.56, 3.36]
SIL026	-0.5	0.699906	2.0%	-0.50 [-1.87, 0.87]
SIL027	0.92	2.077352	0.6%	0.92 [-3.15, 4.99]
SIL028	1.24	1.247726	1.2%	1.24 [-1.21, 3.69]
SIL030	1.1	0.699719	2.0%	1.10 [-0.27, 2.47]
SIL034	2.66	1.069968	1.4%	2.66 [0.56, 4.76]
SIL15	0	2.18	0.5%	0.00 [-4.27, 4.27]
SIL16	-1.2	0.727055	1.9%	-1.20 [-2.63, 0.23]
SIL25	2.3	0.772015	1.8%	2.30 [0.79, 3.81]
SIL35	4.56	0.730352	1.9%	4.56 [3.13, 5.99]
SIL36	1.1	0.612152	2.1%	1.10 [-0.10, 2.30]
SIL40	1.38	0.741728	1.9%	1.38 [-0.07, 2.83]
SIL41b	2.9	0.683699	2.0%	2.90 [1.56, 4.24]
SIL44	1.7	1.270435	1.2%	1.70 [-0.79, 4.19]
SIL51	4.5	0.781353	1.8%	4.50 [2.97, 6.03]
SIL53	2.5	1.549244	0.9%	2.50 [-0.54, 5.54]
TAD005	0.87	0.771589	1.8%	0.87 [-0.64, 2.38]
TAD006	2.3	1.60068	0.9%	2.30 [-0.84, 5.44]
TAD009	1.3	0.612152	2.1%	1.30 [0.10, 2.50]
TAD01	-0.9	1.099852	1.4%	-0.90 [-3.06, 1.26]
TAD012	0.49	0.781353	1.8%	0.49 [-1.04, 2.02]
TAD015	3.3	0.730573	1.9%	3.30 [1.87, 4.73]
TAD018	1.8	0.51001	2.3%	1.80 [0.80, 2.80]
TAD03	0.1	0.783276	1.8%	0.10 [-1.44, 1.64]
TAD06	0.7	0.719907	1.9%	0.70 [-0.71, 2.11]
TAD07	-0.2	1.08075	1.4%	-0.20 [-2.32, 1.92]
TAD08	0.3	0.79963	1.8%	0.30 [-1.27, 1.87]
TAD09	0.4	0.942857	1.6%	0.40 [-1.45, 2.25]
TAD10	1.4	0.689143	2.0%	1.40 [0.05, 2.75]
TAD16	1.1	0.6153	2.1%	1.10 [-0.11, 2.31]
TAD18	1	0.899244	1.6%	1.00 [-0.76, 2.76]
VAR001	2.3	0.7475	1.9%	2.30 [0.83, 3.77]
VAR003	2.6	0.676015	2.0%	2.60 [1.28, 3.92]
VAR006	2.05	0.474335	2.4%	2.05 [1.12, 2.98]
VAR007	1.6	0.994066	1.5%	1.60 [-0.35, 3.55]
VAR015	3.63	4.850045	0.1%	3.63 [-5.88, 13.14]
VAR018	1.4	0.52307	2.3%	1.40 [0.37, 2.43]
VAR019	1.4	0.48541	2.3%	1.40 [0.45, 2.35]
VAR02	1.2	0.594552	2.1%	1.20 [0.03, 2.37]
VAR020	0.48	0.966705	1.5%	0.48 [-1.41, 2.37]
VAR04	3.1	0.783276	1.8%	3.10 [1.56, 4.64]
VAR05	1.5	0.469631	2.4%	1.50 [0.58, 2.42]
VAR11	0.5	0.403791	2.5%	0.50 [-0.29, 1.29]
VAR12	1.3	0.432945	2.4%	1.30 [0.45, 2.15]
Total (95% CI)			**100.0%**	**1.71 [1.36, 2.05]**

Heterogeneity: Tau² = 1.13; Chi² = 184.01, df = 56 (P < 0.00001); I² = 70%
Test for overall effect: Z = 9.57 (P < 0.00001)



Forest plot of comparison: 6 IIEF-EF change scores: RCTs using parallel and crossover design, outcome: 6.1 Effect estimate placebo groups.

Figure 5 (Analysis 6.2)



Forest plot of comparison: 6 IIEF-EF change scores: RCTs using parallel and crossover design, outcome: 6.2 Effect estimate intervention groups.

Figure 6 (Analysis 7.1)



Forest plot of comparison: 7 IIEF-EF change scores: RCTs using parallel design, outcome: 7.1 Effect estimate placebo groups.

Figure 7 (Analysis 7.2)



Forest plot of comparison: 7 IIEF-EF change scores: RCTs using parallel design, outcome: 7.2 Effect estimate intervention groups.

Figure 8 (Analysis 8.1)



Forest plot of comparison: 8 IIEF-EF change scores: RCTs using crossover design, outcome: 8.1 Effect estimate placebo groups.

Figure 9 (Analysis 8.2)



Forest plot of comparison: 8 IIEF-EF change scores: RCTs using crossover design, outcome: 8.2 Effect estimate intervention groups.

Figure 10 (Analysis 9.1)



Forest plot of comparison: 9 IIEF-EF change scores: Commercial Funding, outcome: 9.1 Effect estimate placebo groups.

Figure 11 (Analysis 9.2)



Forest plot of comparison: 9 IIEF-EF change scores: Commercial Funding, outcome: 9.2 Effect estimate intervention groups.

Figure 12 (Analysis 10.1)



Forest plot of comparison: 10 IIEF-EF change scores: Continent, outcome: 10.1 Effect estimate placebo groups.

Figure 13 (Analysis 10.2)



Forest plot of comparison: 10 IIEF-EF change scores: Continent, outcome: 10.2 Effect estimate intervention groups.

Figure 14 (Analysis 11.1)



Forest plot of comparison: 11 IIEF-EF change scores: Single-center study, outcome: 11.1 Effect estimate placebo groups.

Figure 15 (Analysis 11.2)



Forest plot of comparison: 11 IIEF-EF change scores: Single-center study, outcome: 11.2 Effect estimate intervention groups.

Figure 16 (Analysis 12.1)



Forest plot of comparison: 12 IIEF-EF change scores: Type of PDE-5 inhibitor, outcome: 12.1 Effect estimate placebo groups.

Figure 17 (Analysis 12.2)



Forest plot of comparison: 12 IIEF-EF change scores: Type of PDE-5 inhibitor, outcome: 12.2 Effect estimate intervention groups.

Figure 18 (Analysis 13.1)



Forest plot of comparison: 13 IIEF-EF change scores: Prior experience with the intervention, outcome: 13.1 Effect estimate placebo groups.

Figure 19 (Analysis 13.2)



Forest plot of comparison: 13 IIEF-EF change scores: Prior experience with the intervention, outcome: 13.2 Effect estimate intervention groups.

Sources of support

Internal sources

- No sources of support provided

External sources

- No sources of support provided

Feedback

Appendices